Close
Smartlab Europe
Inizio Ignite

Industry Reports

Press Ganey Report on Health Care Safety Culture Prior to and During the COVID-19 Pandemic Finds Downward Trend Continues

Press Ganey released its newest research brief, Reverse the Trend: Improving Safety Culture in the COVID-19 Era. Analyses of national safety culture data and trends prior to and during the COVID-19 pandemic reveal that after a period of modest...

CPhI Report forecasts explosion of contract services growth due to surging INDs and 75 FDA approvals by 2025

A post-pandemic pharma report from CPhI predicts the next few years will deliver strong growth in pharma innovation, with oncology and rare diseases potentially the biggest beneficiaries of positive covid legacies – including accelerated development timelines, remote trials and...

Etihad Cargo Reports 50% Y-O-Y Rise in Pharma Shipments

Etihad Cargo, the cargo and logistics arm of Abu Dhabi-based Etihad Aviation Group, has reported a 50 per cent year-on-year rise in pharma shipments under its specialised PharmaLife product. The double-digit annual growth comes as the carrier marks its second...

Biopharma Market Worth $546.6 billion by 2027

Biopharma market was valued at approximately USD 244.1 Billion in 2019 and is expected to generate revenue of around USD 546.6 Billion by end of 2027, growing at a CAGR of around 10.6% between 2020 and 2027 Market Overview...

Uni-Bio Science Group Announces 2020 Interim Results

A fully integrated biopharmaceutical company - Uni-Bio Science Group Limited, is pleased to announce its interim results for six months ended 30 June 2020 (the "Period"). During the Period, the Group recorded a turnover of HK$67.4 million, representing a...

Turkish Cargo continued its steady growth in 2019

According to the international air cargo information provider WACD's December data (cumulative), the global air cargo brand Turkish Cargo, which serves 127 countries of the world, grew significantly by achieving a tonnage increase of 7.1 percent in a sector...

Novartis to buy The Medicines Company for $9.7bn

Novartis has signed a definitive agreement to acquire US-based The Medicines Company for a total consideration of $9.7bn, or $85 per share. The deal value is said to represent approximately 24% premium over The Medicines Company’s closing share price of...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »